These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. [Melanoma and search for therapeutic targets]. de la Fouchardière A Ann Pathol; 2011 Nov; 31(5 Suppl):S123-4. PubMed ID: 22054449 [No Abstract] [Full Text] [Related]
8. [BRAF mutation testing for the choice of melanoma treatment]. Imianitov EN Arkh Patol; 2012; 74(5):65-71. PubMed ID: 23342664 [TBL] [Abstract][Full Text] [Related]
13. New therapeutic options in the medical management of advanced melanoma. Lutzky J Semin Cutan Med Surg; 2010 Dec; 29(4):249-57. PubMed ID: 21277538 [TBL] [Abstract][Full Text] [Related]
14. Standing on the shoulders of giants. Turajlic S Nat Med; 2019 Mar; 25(3):357. PubMed ID: 30842663 [No Abstract] [Full Text] [Related]
15. Prevalence of exon 15 BRAF mutations in primary melanoma of the superficial spreading, nodular, acral, and lentigo maligna subtypes. Lang J; MacKie RM J Invest Dermatol; 2005 Sep; 125(3):575-9. PubMed ID: 16117801 [TBL] [Abstract][Full Text] [Related]
16. Targeted therapies in melanoma. Moschos SJ; Pinnamaneni R Surg Oncol Clin N Am; 2015 Apr; 24(2):347-58. PubMed ID: 25769717 [TBL] [Abstract][Full Text] [Related]
17. Response to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma. Parakh S; Murphy C; Lau D; Cebon JS; Andrews MC J Clin Pharm Ther; 2015 Feb; 40(1):121-3. PubMed ID: 25382067 [TBL] [Abstract][Full Text] [Related]
18. BRAF inhibitors: research accelerates in wake of positive findings. Brower V J Natl Cancer Inst; 2010 Feb; 102(4):214-5. PubMed ID: 20145213 [No Abstract] [Full Text] [Related]
19. Targeting NRAS in melanoma. Kelleher FC; McArthur GA Cancer J; 2012; 18(2):132-6. PubMed ID: 22453013 [TBL] [Abstract][Full Text] [Related]
20. [Gene abnormalities in melanoma and signal transduction antagonists]. Takada M Gan To Kagaku Ryoho; 2013 Apr; 40(4):453-7. PubMed ID: 23894754 [No Abstract] [Full Text] [Related] [Next] [New Search]